CD273/PD-L2/B7-DC
Alpha Lifetech can provide CD273/PD-L2/B7-DC corresponding products, help each customer's research and development.
01
Introduction To CD273/PD-L2/B7-DC
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD273/PD-L2/B7-DC protein is a common target in medicine.
PD-L2, also known as CD273 and B7-DC, is a B7 family protein member with PD-L1, A cell-surface protein expressed by activated macrophages and dendritic cells, located in chromosome 9, contains 13 exons and 9 internal exons, mainly point mutations, fragment deletion and amplification, with narrow expression range in normal tissues, mainly in macrophages, dendritic cells, mast cells; but highly expressed in lung cancer, urothelial carcinoma, head and neck squamous carcinoma and other tumors. PD-L2 is the second important ligand found after PD-L1 that can be found to bind to PD-1, and PD-L2 plays a role in inhibiting immune cell function after binding to PD-1.
Function of Target CD273/PD-L2/B7-DC
The protein encoded by PD-L2 can bind to PD-1 and thereby function to inhibit immune cell function. PD-L2 can bind to PD-1 and inhibit the immune activation of T cells through downstream signaling pathways, especially tyrosine phosphatase-2 (SHP-2), including lymphocyte-specific protein tyrosine kinase (LcK), phosphatidylinositol 3 (PI3K), mitogen-activated protein kinase (MAPK), and calcium ion signaling pathway. PD-L2 can bind to the repulsive guide molecule b (RGMb) to activate the bone-forming protein receptor pathway and promote the functional activation of T cells. The presence of PD-L2 will inhibit both the activation of T cells and promote the activation of T cells. If PD-L2 is inhibited alone, the purpose of promoting T cell activation may not be achieved.
Gene Pathway of Target CD273/PD-L2/B7-DC
The binding of PD-1 to PD-L1 or PD-L2 leads to the phosphorylation of ITIM and ITSM tyrosine motifs on PD-1 and recruitment of choline phosphatase SHP-2 to reduce phosphorylation of T cell receptor (TCR) signaling molecules. Upon binding to the ligand, the signals activated by PD-1 can also inhibit the PI3K and MAPK pathways, inhibit T cell proliferation, and reduce the production of cytokines and cytotoxic effector molecules. PD-L2 can bind to RGMb to activate the bone-forming protein receptor pathway and promote the functional activation of T cells.
Fig 1: PD-L2 Gene Pathway. (Reference source: Mathios D, Ruzevick J, Jackson CM, et al,. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol. 2015 Jan;121(2):251-9.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD273/PD-L2/B7-DC are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD273/PD-L2/B7-DC protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD273/PD-L2/B7-DC protein products are also essential. Alpha Lifetech can provide CD273/PD-L2/B7-DC corresponding products and help each customer's research and development. In addition, Alpha Lifetech can provide recombinant proteins and Biosimilar antibody products. The effectiveness of the products has been verified through spot products, and we also provide corresponding customized services to help our client companies efficiently and accurately screen corresponding targets through efficient and accurate EC50/IC50. At the same time, Alpha Lifetech also provides services such as recombinant antibody production, recombinant protein production, antibody and protein purification, and affinity verification to ensure the maturity of recombinant antibody affinity and assist customers in antibody drug discovery and subsequent experiments.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64658 | 50ug,100ug,500ug | |
| ALP64636 | 50ug,100ug,500ug | |
| ALP64546 | 50ug,100ug,500ug | |
Reference
[1] Fan Z, Wu C, Chen M, Jiang Y, Wu Y, Mao R, Fan Y. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B. 2022 Mar;12(3):1041-1053.
[2] Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016 Dec 12;7:550.
[3] Mathios D, Ruzevick J, Jackson CM, Xu H, Shah SR, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM, Lim M. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol. 2015 Jan;121(2):251-9.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102